Form 4: Solid Biosciences Officer Sells Shares for Tax Cover

Solid Biosciences' Chief Regulatory Officer, Jessie Hanrahan, sold 12,348 shares of common stock to cover withholding taxes related to vested restricted stock units.

Summary

• Jessie Hanrahan, Chief Regulatory Officer of Solid Biosciences Inc. (SLDB), reported a sale of common stock.
• The transaction involved 12,348 shares of common stock.
• The shares were sold on February 4, 2026, at a weighted average price of $6.4419 per share.
• This sale was not a discretionary trade but was executed solely to cover withholding taxes following the vesting of previously granted restricted stock units.
• The sale was made pursuant to a durable automatic sale instruction letter adopted on August 16, 2024.
• Following the transaction, Jessie Hanrahan beneficially owns 70,327 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale is explicitly for tax purposes related to RSU vesting and not a discretionary decision by the officer, thus not signaling a change in confidence.

Positives

• The sale was non-discretionary, executed solely to cover withholding taxes on vested restricted stock units, indicating no change in management's investment sentiment.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• "This sale was made to cover withholding taxes following the vesting of previously granted restricted stock units pursuant to a durable automatic sale instruction letter adopted by Dr. Hanrahan on August 16, 2024 effecting the sell-to-cover election."
• "The sale does not represent a discretionary trade by Dr. Hanrahan."

Industry Context

StockSavvy.ai notes that routine "sell-to-cover" transactions by executives are common practice in the biotech industry, particularly when restricted stock units vest, and are generally not indicative of a change in fundamental outlook for the company.

Comparison to Industry Standards

• Sell-to-cover transactions are standard practice across all industries, including biotech, for executives receiving equity compensation.
• This type of transaction is comparable to similar tax-related sales seen at companies like Sarepta Therapeutics (SRPT) or BioMarin Pharmaceutical (BMRN) when their executives' RSUs vest.
• The transaction volume of 12,348 shares is relatively small compared to the total shares outstanding for Solid Biosciences, suggesting minimal market impact from this specific insider activity.

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Minimal direct impact as it is a non-discretionary tax-related sale, not signaling a change in insider sentiment. The small volume of shares sold is unlikely to significantly affect market liquidity or price.

Next Steps

• NA

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary "sell-to-cover" transaction by a company officer to satisfy tax obligations upon the vesting of restricted stock units. Such transactions are common and do not typically reflect a change in the officer's outlook on the company's prospects. Therefore, it provides no new fundamental information to warrant a change in investment recommendation, suggesting a "hold" position is appropriate for existing investors.

Keywords

Solid Biosciences, SLDB, Form 4, insider transaction, stock sale, restricted stock units, tax withholding, Jessie Hanrahan, Chief Regulatory Officer